Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate.
about
Dabigatran approaching the realm of heparin-induced thrombocytopeniaChallenges and Treatment for Stroke Prophylaxis in Patients with Atrial Fibrillation in Mexico: A ReviewHow to choose appropriate direct oral anticoagulant for patient with nonvalvular atrial fibrillationStroke prevention in the elderly atrial fibrillation patient with comorbid conditions: focus on non-vitamin K antagonist oral anticoagulantsDifferential benefit risk assessment of DOACs in the treatment of venous thromboembolism: focus on dabigatranProtocol in managing oral surgical patients taking dabigatranAnticoagulation for atrial fibrillation in patients on dialysis: are the benefits worth the risks?No influence of dabigatran anticoagulation on hemorrhagic transformation in an experimental model of ischemic strokeRational Design and Characterization of D-Phe-Pro-D-Arg-Derived Direct Thrombin InhibitorsNew Oral Anticoagulants in Nonvalvular Atrial FibrillationEfficacy and Harms of Direct Oral Anticoagulants in the Elderly for Stroke Prevention in Atrial Fibrillation and Secondary Prevention of Venous Thromboembolism: Systematic Review and Meta-AnalysisDrug-induced liver injury: Towards early prediction and risk stratificationThe Reversal of Direct Oral Anticoagulants in Animal Models.Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in patients with atrial fibrillation--a real patient data analysis in a Hong Kong teaching hospital.2014 AATS guidelines for the prevention and management of perioperative atrial fibrillation and flutter for thoracic surgical procedures.Direct thrombin inhibitors.Dabigatran, a direct thrombin inhibitor, demonstrates antifibrotic effects on lung fibroblasts.Management of gastrointestinal bleeding in patients anticoagulated with dabigatran compared with warfarin: a retrospective, comparative case review.Use of novel oral anticoagulant agents in atrial fibrillation: current evidence and future perspective.Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.Antithrombotic therapy in cardiac embolism.A proposal for dose-adjustment of dabigatran etexilate in atrial fibrillation guided by thrombin timePharmacology, pharmacokinetics, and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor.Novel oral anticoagulants: focus on stroke prevention and treatment of venous thrombo-embolism.[New oral anticoagulant drugs: dabigatran, rivaroxaban and apixaban. Present and future].Dabigatran etexilate: a review of its use for the prevention of venous thromboembolism after total hip or knee replacement surgery.Evaluation of dabigatran for appropriateness of use and bleeding events in a community hospital setting.New options in anticoagulation for the prevention of venous thromboembolism and stroke.Dabigatran versus Enoxaparin in the prevention of venous thromboembolism after total knee arthroplasty: A randomized clinical trialUpdate on anti-coagulation in atrial fibrillation.Medication management of atrial fibrillation: emerging therapies for rhythm control and stroke prevention.Enhanced elimination of dabigatran through extracorporeal methods.Pharmacological basis and clinical evidence of dabigatran therapy.Characterization of thrombin-bound dabigatran effects on protease-activated receptor-1 expression and signaling in vitro.Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.Relationship between plasma dabigatran concentration and activated partial thromboplastin time in Japanese patients with non-valvular atrial fibrillation.Dabigatran in patients with atrial fibrillation: perioperative and periinterventional management.Stroke prevention in atrial fibrillation: understanding the new oral anticoagulants dabigatran, rivaroxaban, and apixabanDecrease in the oral bioavailability of dabigatran etexilate after co-medication with rifampicin.Novel anticoagulants in atrial fibrillation stroke prevention
P2860
Q26744261-9BC15D3E-5DCC-4FEF-85DC-D0BDF2F69FF0Q26765949-E8A4D7BE-4904-4146-959E-B2CC55907969Q26776413-FEF18FC1-A744-469E-B371-643A3C7E5B9AQ26781181-4E6B4E84-465F-499E-B5C1-B01EA5E4F43AQ26799710-D6D973B4-C30F-4DD6-8C19-19200FC9FBE4Q27006890-C16A713D-3648-483E-8732-81B1C33D7033Q27010464-E0C795F5-DEC4-4574-92AD-C58CFE2DE248Q27334041-6CF68C65-8975-4B8A-994F-21B6CEE3F63BQ27678254-0DE095FE-D0BE-4EBA-9C3A-F650E364F515Q28066141-08B9A7CC-B70F-4864-91B0-6F3FE3E0E468Q28085676-3ED8FD7C-66F1-4B7A-8ED4-80C3FF035B37Q28468389-D4B11D10-6543-44E2-9527-56793D0DDFD5Q30491580-04A31D93-5A50-4552-9075-0B1E6FFBC910Q30598904-32B3F336-3DFC-4385-9638-27E69E046BB4Q30653045-CF862FE5-8BFD-43E3-953D-EC4F344FFCB1Q33393692-81EDDF18-56EB-4F95-B0B9-41393A9646ECQ33722844-E07C03A2-C2E1-473B-8F46-6FF2AF0148B3Q33803111-76A3EB65-86E3-42B6-A170-B027E97066F7Q34099930-B4F6B8C7-FF36-4A93-9986-C249E16DB8ECQ34252907-6B9236E8-E03D-4E5C-8836-0AC863864860Q34362901-A616B397-7C72-4FBD-8AE6-9A6B0B4D97E6Q34571082-29904CCC-54AD-4C0F-BC63-A254BF036329Q34611004-BEE8C4BA-7EB1-44BD-AC53-A610FBCEC89DQ34627780-C59BC254-7849-43C0-943B-3F053ABAA352Q34629479-4161DEB7-6776-46D1-83F2-16287C75A3EFQ34638063-81D657ED-501E-4E80-9511-A78AA1B0988CQ34720391-A02C9B13-F98E-46C6-8B5C-8ACFD9AE0891Q34906214-51EDBB45-AB93-490A-B5DB-4B0C9802841CQ35160597-56C1A19B-48C8-4C21-9A5F-E91EF6303E8BQ35172841-984B6AA9-A35E-4772-998F-342349E32655Q35209970-350906FD-7FF9-4AF7-AA73-C0997FEBD8DFQ35210137-B38EDB63-E032-4AB7-AB0B-C9D0F25C4C3CQ35685099-E616ED6A-1205-4E51-A239-111A24C6D127Q35745920-5E67C164-E0A4-4865-97F6-F76B11AB3C8BQ35752573-546CA22A-FB0A-43F6-9FA1-6E2FA09076ECQ36013432-1E914B2F-D6DD-496B-915D-7343A6661E0EQ36025096-633C193B-9B8A-427C-BA22-6FDD46D254C7Q36241389-F40A430C-7F21-49CF-8806-7CBAB48EFE62Q36336046-E51B4943-2317-4E88-B954-0362006380EEQ36443814-7991F6DB-5F56-4CC5-8A5D-D3081D5C662C
P2860
Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate.
description
2008 nî lūn-bûn
@nan
2008 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Clinical pharmacokinetics and ...... nhibitor dabigatran etexilate.
@ast
Clinical pharmacokinetics and ...... nhibitor dabigatran etexilate.
@en
Clinical pharmacokinetics and ...... nhibitor dabigatran etexilate.
@nl
type
label
Clinical pharmacokinetics and ...... nhibitor dabigatran etexilate.
@ast
Clinical pharmacokinetics and ...... nhibitor dabigatran etexilate.
@en
Clinical pharmacokinetics and ...... nhibitor dabigatran etexilate.
@nl
prefLabel
Clinical pharmacokinetics and ...... nhibitor dabigatran etexilate.
@ast
Clinical pharmacokinetics and ...... nhibitor dabigatran etexilate.
@en
Clinical pharmacokinetics and ...... nhibitor dabigatran etexilate.
@nl
P1476
Clinical pharmacokinetics and ...... nhibitor dabigatran etexilate.
@en
P2093
Joachim Stangier
P304
P356
10.2165/00003088-200847050-00001
P577
2008-01-01T00:00:00Z
P6179
1033260698